Correction: Two roads for oncolytic immunotherapy development


This correction notice is to note that second sentence of the first paragraph should be corrected from

‘Globally, there are three approved oncolytic viruses, an adenovirus (H101) for the treatment of advanced head and neck cancer in China, Rigvir, an oncolytic reovirus approved for the treatment of advanced melanoma in Estonia, Latvia, Poland and Belarus, and most notably, talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus, type 1 (HSV-1) approved for the treatment of advanced melanoma in the United States, Europe and Australia.’

To

‘Globally, there are three approved oncolytic viruses, an adenovirus (H101) for the treatment of advanced head and neck cancer in the People’s Republic of China; Rigvir, an oncolytic echovirus approved for the treatment of advanced melanoma in some Eastern European countries; and most notably, talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus, type 1 (HSV-1) approved for the treatment of advanced melanoma in the United States, Europe, Australia and Israel.’

Open access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

J Immunother Cancer 2021;9:e0515-2corr1. doi:10.1136/s40425-019-0515-2corr1

Check for updates